Progress of Research on Radiotherapy for Advanced Esophageal Cancer in the Era of Immunotherapy

Esophageal cancer is predominantly diagnosed at a locally advanced or distant metastasis stage in patients. Once the disease progresses to the advanced stage, its prognosis is poor, and the median overall survival time of patients receiving traditional chemotherapy is less than one year. Treatment w...

Full description

Saved in:
Bibliographic Details
Published inZhongliu fangzhi yanjiu Vol. 51; no. 6; pp. 397 - 401
Main Author Wang, Lan
Format Journal Article
LanguageChinese
Published Tianjin China Anti-Cancer Association 01.06.2024
Magazine House of Cancer Research on Prevention and Treatment
Subjects
advanced esophageal cancer
Cancer
Chemotherapy
Esophageal cancer
Esophagus
Health services
Immune checkpoint inhibitors
Immunotherapy
Metastases
Patients
PD-1 protein
Radiation therapy
radiotherapy
Survival
Online AccessGet full text

Cover

More Information
Summary:Esophageal cancer is predominantly diagnosed at a locally advanced or distant metastasis stage in patients. Once the disease progresses to the advanced stage, its prognosis is poor, and the median overall survival time of patients receiving traditional chemotherapy is less than one year. Treatment with immune checkpoint inhibitors has provided new opportunities to patients with esophageal cancer and changed the previous treatment pattern. Chemotherapy combined with immunotherapy（PD-1 inhibitor） has become the standard first-line treatment for advanced esophageal cancer. However, chemotherapy combined with immunotherapy have been reported a median overall survival time of only 12.4-17.2 months for patients.Such a survival time remains insufficient to meet clinical needs. Combining systemic treatment with local treatment and seeking new comprehensive treatment models are important research directions for improving efficacy. This article reviews the research progress and prospects of radiotherapy in the treatmen
ISSN:1000-8578
DOI:10.3971/j.issn.1000-8578.2024.24.0065